door < dopa < dopamine

Facettes :

List of bibliographic references indexed by dopa

Number of relevant bibliographic references: 53.
[0-50] [0 - 20][0 - 50][50-52][50-70]

Ident.	Authors (with country if any)	Title
000141 (2011)	Lynn Rochester [Royaume-Uni] ; Katherine Baker [Royaume-Uni] ; Alice Nieuwboer [Belgique] ; David Burn [Royaume-Uni]	Targeting dopa‐sensitive and dopa‐resistant gait dysfunction in Parkinson's disease: Selective responses to internal and external cues
000408 (2011)	Catherine L. Gallagher [États-Unis] ; Bradley T. Christian [États-Unis] ; James E. Holden [États-Unis] ; Onofre T. Dejesus [États-Unis] ; Robert J. Nickles [États-Unis] ; Laura Buyan-Dent [États-Unis] ; Barbara B. Bendlin [États-Unis] ; Sandra J. Harding [États-Unis] ; Charles K. Stone [États-Unis] ; Barb Mueller [États-Unis] ; Sterling C. Johnson [États-Unis]	A within‐subject comparison of 6‐[18F]fluoro‐m‐tyrosine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease
000A57 (2009)	Michael Niehues [Allemagne] ; Hensel [Allemagne]	In‐vitro interaction of l‐dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability?
000B43 (2009)	A H Evans [Australie, Royaume-Uni] ; A D Lawrence [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]	Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson’s disease
000B79 (2009)	Anna Brück [Finlande] ; Sargo Aalto [Finlande] ; Elina Rauhala [Finlande] ; Jörgen Bergman [Finlande] ; Reijo Marttila [Finlande] ; Juha O. Rinne [Finlande]	A follow‐up study on 6‐[18F]fluoro‐L‐dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen
000D45 (2008)	Peter Jenner [Royaume-Uni]	Molecular mechanisms of L-DOPA-induced dyskinesia
001015 (2007)	Stefano Zoccolella [Italie] ; Giovanni Iliceto [Italie] ; Michele Demari [Italie] ; Paolo Livrea [Italie] ; Paolo Lamberti [Italie]	Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review
001197 (2006)	Anna L. Bartels [Pays-Bas] ; Bauke M. De Jong [Pays-Bas] ; Nir Giladi [Israël] ; Joanna D. Schaafsma [Pays-Bas] ; R. Paul Maguire [Pays-Bas] ; Lammy Veenma [Pays-Bas] ; Jan Pruim [Pays-Bas] ; Yacov Balash [Israël] ; Moussa B. H. Youdim [Israël] ; Klaus L. Leenders [Pays-Bas]	Striatal dopa and glucose metabolism in PD patients with freezing of gait
001322 (2006)	Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]	Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
001412 (2005)	Mariese A. Hely [Australie] ; John G. L. Morris [Australie] ; Wayne G. J. Reid [Australie] ; Robert Trafficante [Australie]	Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
001574 (2004)	Fabio Guerini [Italie] ; Giovanni B. Frisoni [Italie] ; Catherine Bellwald [Italie] ; Roberta Rossi Psy [Italie] ; Giuseppe Bellelli [Italie] ; Marco Trabucchi [Italie]	Subcortical Vascular Lesions Predict Functional Recovery After Rehabilitation in Patients with L‐Dopa Refractory Parkinsonism
001A22 (2001)	Elina Nurmi [Finlande] ; Hanna M. Ruottinen [Finlande] ; Jörgen Bergman [Finlande] ; Merja Haaparanta [Finlande] ; Olof Solin [Finlande] ; Pirkko Sonninen [Finlande] ; Juha O. Rinne [Finlande]	Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET study
001B10 (2001)	P. K. Pal [Canada] ; C. S. Lee [Canada] ; A. Samii [Canada] ; M. Schulzer [Canada] ; A. J. Stoessl [Canada] ; E. K. Mak [Canada] ; J. Wudel [Canada] ; T. Dobko [Canada] ; J. K. C. Tsui [Canada]	Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET [18F]-DOPA Ki
001C34 (2000)	J. Lyytinen [Finlande] ; S. Kaakkola [Finlande] ; A. Gordin [Finlande] ; E.-R Kultalahti [Finlande] ; H. Ter V Inen [Finlande]	Entacapone and selegiline with l-dopa in patients with Parkinson's disease: an interaction study
001D65 (1999)	C. S. Biggs [Royaume-Uni] ; M. S. Starr [Royaume-Uni]	Microdialysis study of the effects of the antiparkinsonian drug budipine on L‐DOPA‐induced release of dopamine and 5‐hydroxytryptamine by rat substantia nigra and corpus striatum
001D72 (1999)	Taylor [Royaume-Uni] ; Beerahee [Royaume-Uni] ; Citerone [États-Unis] ; Cyronak [États-Unis] ; Leigh [Royaume-Uni] ; Fitzpatrick [Royaume-Uni] ; Lopez‐Gil [Royaume-Uni] ; Vakil [Royaume-Uni] ; Burns [Royaume-Uni] ; Lennox [Royaume-Uni]	Lack of a Pharmacokinetic Interaction at Steady State Between Ropinirole and L‐Dopa in Patients with Parkinson's Disease
001D86 (1999)	J. S. Rakshi ; T. Uema ; K. Ito ; D. L. Bailey ; P. K. Morrish ; J. Ashburner ; A. Dagher ; I. H. Jenkins ; K. J. Friston ; D. J. Brooks	Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [18F]dopa-PET study
001E01 (1999)	Yasushi Ito [Japon] ; Masahiro Fujita [Japon] ; Shoichi Shimada ; Yoshiyuki Watanabe [Japon] ; Tomoya Okada [Japon] ; Hideo Kusuoka [Japon] ; Masaya Tohyama [Japon] ; Tsunehiko Nishimura [Japon]	Comparison between the decrease of dopamine transporter and that of L‐DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models
001E50 (1998)	Mark D. Lindner [États-Unis] ; Dwaine F. Emerich [États-Unis]	Therapeutic Potential of a Polymer-Encapsulated l-DOPA and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson’s Disease
001E55 (1998)	C. S. Biggs [Royaume-Uni] ; A. Fisher [Royaume-Uni] ; M. S. Starr [Royaume-Uni]	The antiparkinsonian drug budipine stimulates the activity of aromatic L‐amino acid decarboxylase and enhances L‐DOPA‐induced dopamine release in rat substantia nigra
001F04 (1998)	Jeon [Corée du Sud] ; Jae-Min Jeong [Corée du Sud] ; Sung-Sup Park [Corée du Sud] ; Jong-Min Kim [Corée du Sud] ; Young-Soo Chang [Corée du Sud] ; Ho-Chun Song [Corée du Sud] ; Kyeong-Min Kim [Corée du Sud] ; Keun-Young Yoon [Corée du Sud] ; Myung-Chul Lee [Corée du Sud] ; Sang-Bok Lee [Corée du Sud]	Dopamine transporter density measured by [123I]β‐CIT single‐photon emission computed tomography is normal in dopa‐responsive dystonia
001F13 (1998)	Ronald K. B. Pearce [Royaume-Uni] ; Tara Banerji [Royaume-Uni] ; Jenner [Royaume-Uni] ; C. David Marsden [Royaume-Uni]	De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmoset
002037 (1997)	Piccini [Royaume-Uni] ; P. K. Morrish [Royaume-Uni] ; N. Turjanski [Royaume-Uni] ; G. V. Sawle [Royaume-Uni] ; D. J. Burn [Royaume-Uni] ; R. A. Weeks [Royaume-Uni] ; M. H. Mark [États-Unis] ; D. M. Maraganore [États-Unis] ; Andrew Lees (neurologue) [Royaume-Uni] ; D. J. Brooks [Royaume-Uni]	Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study
002123 (1996)	Hugues Duffau [France] ; Nathalie Tzourio [France] ; Dominique Caparros-Lefebvre [France] ; Fabrice Parker [France] ; Bernard Mazoyer [France]	Tremor and voluntary repetitive movement in Parkinson's disease: comparison before and after l -dopa with positron emission tomography
002278 (1995)	A. Fredriksson ; T. Archer [Suède]	Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice
002280 (1995)	H. Ueda [Japon] ; K. Sato [Japon] ; F. Okumura [Japon] ; A. Inoue [Japon] ; Y. Nakata [Japon] ; N. Ozaki [Japon] ; J. L. Yue [Japon] ; Y. Misu [Japon]	Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson's disease model rats
002561 (1993)	E. Fertl [Autriche] ; E. Auff [Autriche] ; A. Doppelbauer [Autriche] ; F. Waldhauser [Autriche]	Circadian secretion pattern of melatonin in de novo Parkinsonian patients: evidence for phase-shifting properties of l-dopa
002644 (1992)	H. Przuntek [Allemagne] ; D. Welzel [Allemagne] ; E. Blümner [Allemagne] ; W. Danielczyk [Autriche] ; H. Letzel [Allemagne] ; -J. Kaiser [Allemagne] ; H. Kraus [Allemagne] ; P. Riederer [Allemagne] ; D. Schwarzmann [Allemagne] ; H. Wolf [Allemagne] ; K. Überla [Allemagne]	Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued
002645 (1992)	S. Sarre [Belgique] ; P. Herregodts [Belgique] ; D. Deleu [Belgique] ; A. Devrieze [Belgique] ; N. De Klippel [Belgique] ; G. Ebinger [Belgique] ; Y. Michotte [Belgique]	Biotransformation of l -DOPA in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study
002726 (1991)	Anne-Marie Ferrandez [France] ; Olivier Blin	A comparison between the effect of intentional modulations and the action of l-Dopa on gait in Parkinson's disease
002815 (1989)	F. Boomsma [Pays-Bas] ; D. Meerwaldt [Pays-Bas] ; J. Man In'T Veld [Pays-Bas] ; A. Hovestadt [Pays-Bas] ; H. Schalekamp [Pays-Bas]	Treatment of idiopathic parkinsonism with l -dopa in the absence and presence of decarboxylase inhibitors: effects on plasma levels of l -dopa, dopa decarboxylase, catecholamines and 3-O-methyl-dopa
002822 (1989)	G. J. D. Birkmayer [Autriche] ; W. Birkmayer [Autriche]	Stimulation of endogenous L‐dopa biosynthesis — a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH)
002834 (1989)	W. Jung [Allemagne] ; H. Herken [Allemagne]	Inhibition of biopterin synthesis and DOPA production in PC-12 pheochromocytoma cells induced by 6-aminonicotinamide
002886 (1988)	M. Hietanen [Finlande] ; Teräväinen [Finlande]	Dementia and treatment with L‐dopa in Parkinson's disease
002922 (1987)	Diamond [États-Unis] ; Charles H. Marchkham [États-Unis] ; Marchgaret M. Hoehn [États-Unis] ; Fletcher H. Mcdowell [États-Unis] ; Manfred D. Muenter [États-Unis]	Multi‐center study of Parkinson mortality with early versus later dopa treatment
002966 (1986)	Markham [États-Unis] ; Shirley G. Diamond [États-Unis]	Long‐term follow‐up of early dopa treatment in Parkinson's disease
002A19 (1985)	Charlotte Sachs [Suède] ; Bo Berglund [Suède] ; Lennart Kaijser [Suède]	Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa‐decarboxylase inhibition
002B07 (1982)	M. Markianos [Grèce] ; M. Hadjikonstantinou [Grèce] ; E. Bistolaki [Grèce]	Urinary noradrenaline and serotonin metabolites in drug‐free Parkinson patients and the effect of L‐dopa treatment
002B72 (1980)	Eldad Melamed [États-Unis] ; Franz Hefti [États-Unis] ; Richard J. Wurtman [États-Unis]	Nonaminergic striatal neurons convert exogenous l‐dopa to dopamine in parkinsonism
002B88 (1979)	J. Vardi [Israël] ; H. Glaubman [Israël] ; J. Rabey [Israël] ; M. Streifler [Israël]	EEG sleep patterns in Parkinsonian patients treated with Bromocryptine and L-Dopa: A comparative study
002B99 (1978)	H. Belmaker [Israël] ; P. Ebstein [Israël] ; J. Biederman [Israël] ; R. Stern [Israël] ; M. Berman [Israël] ; M. Van Praag [Israël]	The effect of l -dopa and propranolol on human CSF cyclic nucleotides
002C03 (1978)	J. Vardi [Israël] ; H. Glaubman [Israël] ; M. Rabey [Israël] ; M. Streifler [Israël]	Myoclonic attacks induced by L-Dopa and Bromocryptin in Parkinson patients
002C04 (1978)	Leontino Battistin [Italie] ; Giorgio Meneghetti [Italie] ; Simone Rigotti [Italie] ; Aldo Saia [Italie]	Long‐term treatment of Parkinson's disease with L‐Dopa and Dopa‐decarboxylase inhibitor: Therapeutic results and side effects
002C22 (1977)	Jes Gerlach [Danemark]	Relationship between tardive dyskinesia, l -Dopa-induced hyperkinesia and parkinsonism
002C32 (1977)	G. Campanella [Italie] ; S. Algeri [Italie] ; C. Cerletti [Italie] ; E. Dolfini [Italie] ; A. Jori [Italie] ; F. Rinaldi [Italie]	Correlation of clinical symptoms, HVA and 5-HIAA in CSF and plasma L-DOPA in parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602
002C56 (1975)	W. Birkmayer [Autriche] ; P. Riederer [Autriche] ; H. Youdim [Autriche] ; W. Linauer [Autriche]	The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil
002C69 (1974)	W. Birkmayer [Autriche] ; W. Danielczyk [Autriche] ; E. Neumayer [Autriche] ; P. Riederer [Autriche]	Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findings
002C83 (1973)	W. Birkmayer [Autriche] ; W. Danielcyk [Autriche] ; E. Neumayer [Autriche] ; P. Riederer [Autriche]	L-dopa level in plasma, primary condition for the kinetic effect
002C94 (1972)	K. Rinne [Finlande] ; V. Sonninen [Finlande] ; T. Siirtola [Finlande]	Treatment of Parkinson's disease with l -DOPA and decarboxylase inhibitor
002D07 (1971)	J. Chaco [Israël] ; O. Abramsky [Israël]	The effect of L-DOPA on postural reflexes in parkinson's disease
002D18 (1970)	Harold Klawans Jr [États-Unis] ; M. M. Ilahi [États-Unis] ; David Shenker [États-Unis]	THEORETICAL IMPLICATIONS OF THE USE OF L‐DOPA IN PARKINSONISM.

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "dopa" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i  \
                -Sk "dopa" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Title.i
   |clé=    dopa
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024